Anzeige
Mehr »
Mittwoch, 30.07.2025 - Börsentäglich über 12.000 News
Der Daten-Boom frisst Energie - Uran ist die Antwort!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQGU | ISIN: CA4236943060 | Ticker-Symbol: 2VF0
Tradegate
25.07.25 | 09:55
0,090 Euro
+5,29 % +0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HEMOSTEMIX INC Chart 1 Jahr
5-Tage-Chart
HEMOSTEMIX INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0700,09829.07.
0,0800,08729.07.

Aktuelle News zur HEMOSTEMIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SaHemostemix Inc (2): Hemostemix $517,230 (U.S.) debenture private placement2
FrHemostemix Inc (2): Hemostemix closes $2.96-million private placement1
DoHemostemix Inc.: Hemostemix Closes $2,969,600 Private Placement308Calgary, Alberta--(Newsfile Corp. - July 24, 2025) - Further to Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") June 26 and July 9th press releases, the Company...
► Artikel lesen
DoHemostemix Inc (2): Hemostemix closes sale of 15 ACP-01 debentures5
HEMOSTEMIX Aktie jetzt für 0€ handeln
23.07.Hemostemix Inc.: Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture135Calgary, Alberta--(Newsfile Corp. - July 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely...
► Artikel lesen
18.07.Hemostemix Inc (2): Hemostemix closes $3-million oversubscribed placement4
17.07.Hemostemix Inc.: Hemostemix Closing $3,000,000 Private Placement353Calgary, Alberta--(Newsfile Corp. - July 17, 2025) - Further to the June 26 and July 9th press releases announcing the Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
► Artikel lesen
11.07.Hemostemix Inc (2): Hemostemix 3,911,385-share private placement2
10.07.Hemostemix Inc (2): Hemostemix closes $2.7M first tranche of placement1
09.07.Hemostemix Inc.: Hemostemix Oversubscribed, Closing $2,700,000 Private Placement and Settles $400,000 of Debt at $0.20 per Share224Calgary, Alberta--(Newsfile Corp. - July 9, 2025) - Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") non brokered private placement of $2,500,000 announced June...
► Artikel lesen
04.07.Hemostemix Inc (2): Hemostemix closes $469,366 private placement4
04.07.Hemostemix Inc.: Hemostemix Closes $469,366 Private Placement416Calgary, Alberta--(Newsfile Corp. - July 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces that the TSX Venture Exchange ("TSXV") conditionally...
► Artikel lesen
03.07.Hemostemix Inc.: Hemostemix Announces its 10th Publication: A Molecular Strategy for the Treatment of Heart Failure: Response to BioCardia's Cardiamp Heart Failure Trial424Calgary, Alberta--(Newsfile Corp. - July 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is proud to share the Journal of Biomedical Research and Environmental Science published Autologous...
► Artikel lesen
02.07.Hemostemix Inc (2): Hemostemix sees Florida pass stem cell therapy bill2
02.07.Hemostemix Inc.: Hemostemix's VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!272Calgary, Alberta--(Newsfile Corp. - July 2, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a clinical-stage biotechnology company focused on autologous stem cell therapies for cardiovascular...
► Artikel lesen
27.06.Hemostemix Inc.: Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch303Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem cell therapy company and Mr. Croom Lawrence are pleased to announce...
► Artikel lesen
27.06.Hemostemix Inc (2): Hemostemix chairman Lacey subscribes for $1.5M in units5
26.06.Hemostemix Inc.: Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture159Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company...
► Artikel lesen
17.06.Hemostemix Inc.: Hemostemix Closes Private Placement of $469,366305Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement...
► Artikel lesen
30.05.Hemostemix Inc (2): Hemostemix 1,634,466-share private placement3
Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1